XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.
Breast Cancer
DRUG: capecitabine|DRUG: docetaxel
Progression-free Survival (PFS), The time from enrollment until disease progression, assessed as the time to tumor progression, as evaluated by regular examinations per routine clinical practice, or death from any cause., approximately 2 years
Time to Treatment Failure, The time from enrollment to discontinuation of any drug of the treatment combination., approximately 2 years|Overall Response Rate, The percentage of participants with complete or partial remission, based on evaluation of tumor responses assessed at regular examinations per routine clinical practice., approximately 2 years|Clinical Benefit Rate, The percentage of participants with an overall response (complete or partial remission) or with stable disease., approximately 2 years|Duration of Treatment With Xeloda, approximately 2 years|Percentage of Capecitabine Dose Modifications, approximately 2 years|Number of Participants With Adverse Events, approximately 2 years
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.